Recce Pharmaceuticals (RCE) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure InfectionsJanuary 22 at 10:54 PM | markets.businessinsider.com'Significant' new milestone for Recce in clinical testing of skin infection gelJanuary 21 at 9:59 PM | msn.comRecce Pharmaceuticals doses all patients in phase II skin infection trialJanuary 21 at 9:59 PM | msn.comRecce Pharmaceuticals Completes Patient Dosing in Phase II Trial for Topical GelJanuary 20 at 6:37 PM | tipranks.comRoad to 2025: Recce’s calendar of clinical accomplishmentDecember 23, 2024 | msn.comRecce gets Indonesian nod for phase III trial of diabetic foot infection treatmentDecember 8, 2024 | msn.comRecce Pharmaceuticals advances global reach with Indonesia’s approval for Phase 3 Diabetic Foot Infection TrialDecember 8, 2024 | msn.comInvestors in Recce Pharmaceuticals (ASX:RCE) have seen notable returns of 68% over the past five yearsDecember 2, 2024 | uk.finance.yahoo.comRecce Pharmaceuticals Highlights Risks and Cautions InvestorsNovember 27, 2024 | tipranks.comRecce Pharmaceuticals Granted Australia Patent for RECCE® Anti-InfectivesNovember 27, 2024 | markets.businessinsider.comComplete patent protection for 2 Recce anti-infective treatmentsNovember 27, 2024 | msn.comRecce Pharmaceuticals Secures Global Patent for Anti-InfectivesNovember 26, 2024 | markets.businessinsider.comASX health stocks fighting superbugs to save livesNovember 20, 2024 | msn.comRecce scores $6.75M R&D rebateNovember 14, 2024 | msn.comRecce Pharmaceuticals Boosted by $6.75M R&D RebateNovember 14, 2024 | markets.businessinsider.comRecce Pharmaceuticals garners ethics approval for anti-infective Phase 3 clinical trial in IndonesiaNovember 11, 2024 | au.investing.comBreak it Down: Recce Pharmaceuticals gets Indonesian entry for clinical trialNovember 11, 2024 | msn.comRecce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infectionsNovember 11, 2024 | msn.comRecce Pharmaceuticals Advances Phase 3 Trial in IndonesiaNovember 11, 2024 | markets.businessinsider.comRecce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure InfectionsNovember 7, 2024 | markets.businessinsider.comRecce Pharmaceuticals Outlines Future Plans Amid UncertaintiesNovember 7, 2024 | markets.businessinsider.comRecce reaches key dosing milestone in testing of skin infection gelNovember 5, 2024 | msn.comRecce Pharmaceuticals Advances in Promising Skin Infection TrialNovember 5, 2024 | markets.businessinsider.comRecce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical TrialOctober 31, 2024 | markets.businessinsider.comRecce gets nod to progress Phase 2 trial for skin infectionsOctober 28, 2024 | msn.comRecce Pharmaceuticals’ R327 Gel Shows Promising Trial ResultsOctober 28, 2024 | msn.comRecce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure InfectionsOctober 11, 2024 | markets.businessinsider.comHealth Check: Fresh from its FDA win, Echo IQ aims for even bigger heart failure approvalOctober 9, 2024 | msn.comRecce progresses testing of gel to treat bacterial skin infectionsOctober 9, 2024 | msn.comstrongRecce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger/strongOctober 1, 2024 | msn.comRecce eyes Indonesia for novel anti-infective as Indo-Aus ties grow strongerOctober 1, 2024 | msn.comHealth Kick Podcast: Talking antibiotics with Recce PharmaceuticalsSeptember 25, 2024 | msn.comRecce’s reconnaissance against superbug – infiltrate, eliminate, escape undetectedSeptember 6, 2024 | msn.comR9Q.SG,0P0001JYFK,0 (R9Q.SG)September 1, 2024 | nz.finance.yahoo.comRecce Pharmaceuticals Announces Successful Completion of Share Purchase PlanAugust 6, 2024 | markets.businessinsider.comRecce Pharmaceuticals Ltd (RCE.XA)July 28, 2024 | nz.finance.yahoo.comRecce Pharmaceuticals Ltd (R9Q.F)July 28, 2024 | nz.finance.yahoo.comRecce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical TrialMay 17, 2024 | finance.yahoo.comRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot StudyMay 13, 2024 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in China for RECCE® Anti-InfectivesMay 8, 2024 | finance.yahoo.comRecce Pharmaceuticals granted China patent for RECCE® Anti-InfectivesMay 7, 2024 | au.investing.comASX Health Stocks: Recce scores patent win in China for its infection drugsMay 7, 2024 | msn.comRecce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisApril 30, 2024 | finance.yahoo.comRecce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)April 17, 2024 | finance.yahoo.comRecce Pharmaceuticals Provides Business UpdateApril 10, 2024 | finance.yahoo.comRecce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024April 9, 2024 | finance.yahoo.comRecce pharmaceuticals granted new patent in Israel for anti-infectivesApril 4, 2024 | seekingalpha.comRecce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-InfectivesApril 4, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP PortfolioMarch 22, 2024 | finance.yahoo.comRecce hits milestone in Phase I/II trial for UTIs and urosepsisMarch 19, 2024 | msn.com Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address RCE Media Mentions By Week RCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCE News Sentiment▼0.410.64▲Average Medical News Sentiment RCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCE Articles This Week▼41▲RCE Articles Average Week Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Apollomics News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:RCE) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTexas embraces new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Recce Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCE Stock Alerts